REVB, REVBW · CIK 0001810560 · operating
Revelation Biosciences is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing immune system therapeutics and diagnostics. The company was incorporated in 2019 as Petra Acquisition, Inc. and rebranded to Revelation Biosciences in January 2022. Operating with a small team of eight full-time employees, the company remains in early developmental stages without commercial revenue generation.
The company's pipeline centers on two therapeutic candidates targeting kidney disease. GEM-AKI is being developed for the prevention and treatment of acute kidney injury, while GEM-CKD addresses chronic kidney disease prevention and treatment. Both programs are positioned within the company's broader focus on immune system modulation as a therapeutic approach. No material revenue streams have been established as the company remains pre-commercial and focused on clinical development activities.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-23.95 | $-23.95 | +72.7% | |
| 2024 | $-87.68 | $-87.68 | -16443.4% | |
| 2023 | $-0.53 | $-0.53 | +97.4% | |
| 2022 | $-20.09 | $-20.09 | -1617.1% | |
| 2021 | — | $-1.17 | — | |
| 2020 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001193125-26-076552 | SEC ↗ |
| 2024-12-31 | 2025-03-06 | 0000950170-25-034584 | SEC ↗ |
| 2023-12-31 | 2024-03-22 | 0000950170-24-035322 | SEC ↗ |
| 2022-12-31 | 2023-03-30 | 0000950170-23-011000 | SEC ↗ |
| 2021-12-31 | 2022-04-15 | 0001213900-22-020179 | SEC ↗ |
| 2020-12-31 | 2021-03-31 | 0001213900-21-019097 | SEC ↗ |